成纤维细胞活化蛋白
体内分布
化学
正电子发射断层摄影术
癌症研究
人血清白蛋白
Spect成像
靶向治疗
成纤维细胞
核医学
癌症
医学
生物化学
体外
内科学
作者
Lingxin Meng,Jianyang Fang,Liang Zhao,Tingting Wang,Pu Yuan,Zuoquan Zhao,Rongqiang Zhuang,Qin Lin,Haojun Chen,Xiaoyuan Shawn Chen,Xianzhong Zhang,Zhide Guo
标识
DOI:10.1021/acs.jmedchem.1c02162
摘要
The fibroblast activation protein (FAP), overexpressed on cancer-associated fibroblasts (CAFs), has become a valuable target for tumor diagnosis and therapy. However, most FAP-based radioligands show insufficient tumor uptake and retention. In this study, three novel albumin-binding FAP ligands (denoted as FSDD 0 I, FSDD 1 I, and FSDD 3 I) were labeled with 68 Ga and 177 Lu to overcome these limitations. Cell-based studies and molecular docking assays were performed to identify the specificity and protein-binding properties for FAP. Positron emission tomography (PET) scans in human hepatocellular carcinoma patient-derived xenografts (HCC-PDXs) animal models revealed longer blood retention of 68 Ga-FSDD 0 I than 68 Ga-FAPI-04, 68 Ga-FSDD 1 I, and 68 Ga-FSDD 3 I. Remarkably, 68 Ga-FSDD 3 I had prominent tumor-to-nontarget (T/NT) ratios. The prominent tumor retention properties of 177 Lu-FSDD 0 I in single photon emission computed tomography (SPECT) imaging and biodistribution studies were demonstrated. In summary, this study reports a proof-of-concept study of albumin-binding radioligands for FAP-targeted imaging and targeted radionuclide therapy (TRT).
科研通智能强力驱动
Strongly Powered by AbleSci AI